High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer
Authors
Keywords
-
Journal
GENES CHROMOSOMES & CANCER
Volume 55, Issue 1, Pages 30-44
Publisher
Wiley
Online
2015-09-23
DOI
10.1002/gcc.22297
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer
- (2015) Moritz Jesinghaus et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A Mass Spectrometry Assay to Simultaneously Analyze ROS1 and RET Fusion Gene Expression in Non–Small-Cell Lung Cancer
- (2015) Priyanga Wijesinghe et al. Journal of Thoracic Oncology
- Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer
- (2015) M. Pekar-Zlotin et al. ONCOLOGIST
- Semiconductor-Based Sequencing of Formalin-Fixed, Paraffin-Embedded Colorectal Cancer Samples
- (2015) A. Stenzinger et al. ONCOLOGIST
- Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor
- (2014) J. K. Won et al. ANNALS OF ONCOLOGY
- Immunohistochemistry, Fluorescence in Situ Hybridization, and Reverse Transcription–Polymerase Chain Reaction for the Detection of Anaplastic Lymphoma Kinase Gene Rearrangements in Patients With Non–Small Cell Lung Cancer: Potential Advantages and Methodologic Pitfalls
- (2014) Irina Demidova et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Lung Cancers with ConcomitantEGFRMutations andALKRearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation
- (2014) Jin-Ji Yang et al. CLINICAL CANCER RESEARCH
- ROS1expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases
- (2014) Arne Warth et al. HISTOPATHOLOGY
- Multicenter Immunohistochemical ALK-Testing of Non–Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria
- (2014) Maximilian von Laffert et al. Journal of Thoracic Oncology
- Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing
- (2014) Evgeny A. Moskalev et al. LUNG CANCER
- TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC
- (2014) Blanka Robesova et al. LUNG CANCER
- Anchored multiplex PCR for targeted next-generation sequencing
- (2014) Zongli Zheng et al. NATURE MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- COSMIC: exploring the world's knowledge of somatic mutations in human cancer
- (2014) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives
- (2014) Haiquan Chen et al. OncoTargets and Therapy
- Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer
- (2014) Johanna N. Spaans et al. Frontiers in Oncology
- EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype
- (2013) A. Warth et al. EUROPEAN RESPIRATORY JOURNAL
- Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment
- (2013) Reinhard Buettner et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Diagnostic Profiling of Lung Cancer Specimens with a Semiconductor-Based Massive Parallel Sequencing Approach
- (2013) Volker Endris et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
- (2013) Neal I. Lindeman et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): Results of a multi-centre ALK-testing
- (2013) Maximilian v. Laffert et al. LUNG CANCER
- ClinVar: public archive of relationships among sequence variation and human phenotype
- (2013) Melissa J. Landrum et al. NUCLEIC ACIDS RESEARCH
- Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification
- (2012) William D. Travis et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement,ALKsignal copy number, and response to crizotinib therapy inALKfluorescence in situ hybridization-positive nonsmall cell lung cancer
- (2012) D. Ross Camidge et al. CANCER
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Quantitative Analysis of Diagnostic Guidelines for HER2-Status Assessment
- (2012) Albrecht Stenzinger et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK
- (2012) Jong-Mu Sun et al. Journal of Thoracic Oncology
- Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell Lung Cancer
- (2012) Nir Peled et al. Journal of Thoracic Oncology
- Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent
- (2012) Chris M.J. Conklin et al. Journal of Thoracic Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- (2012) Doron Lipson et al. NATURE MEDICINE
- KIF5B-RET fusions in lung adenocarcinoma
- (2012) Takashi Kohno et al. NATURE MEDICINE
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
- (2011) Y. S. Ju et al. GENOME RESEARCH
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
- (2010) M. Mino-Kenudson et al. CLINICAL CANCER RESEARCH
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene
- (2009) Tsuyoshi Takahashi et al. ANNALS OF SURGICAL ONCOLOGY
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset
- (2009) Kentaro Inamura et al. MODERN PATHOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now